Oppenheimer analyst Hartaj Singh maintained a Buy rating on Cellectis SA (CLLS) today and set a price target of $44. The company’s shares opened today at $17.99, close to its 52-week low of $15.34.
Singh wrote:
“Cellectis (CLLS) on 03/12 reported 4Q18 sales/earnings. Focuses of the call were on clinical updates toward year-end 2019, with CLLS indicating that varying levels of clinical data would be presented for all three proprietary projects, UCART123, UCART22 and (potentially) UCARTCS1. Since CLLS is in the dose escalation phase for YE19 data dependency is a function of dose escalation, non-linear in clinical trials. We believe that the uniqueness of CLLS’s allogeneic technology manifested itself in technological challenges to gene editing and manufacturing scale-up, both issues that the company has been able to address. We also believe CLLS will be able to address the unique challenges allogeneic CAR- T possesses in clinical drug development. We update estimates for results/guidance and stay bullish.”
According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.9% and a 42.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
Cellectis SA has an analyst consensus of Moderate Buy, with a price target consensus of $30.33.
See today’s analyst top recommended stocks >>
Based on Cellectis SA’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.84 million. In comparison, last year the company had a GAAP net loss of $28.51 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants.
